Within a project entitled “Immunotherapy and the diagnosis of Alzheimer´s disease" MIVAC scientists in collaboration with MIVAC Development AB have developed a specific antibody against toxic components that cause Alzheimer´s disease. The verification grant will be used to verify the antibody´s active mechanism and to show proof of concept through a variety of studies. The end goal is to develop this antibody into both a drug and a diagnostic tool. 

“The verification grant will truly help us drive the project under a particularly value-enhancing commercial development phase and will also benefit the project´s scope for attracting continued financing, thus securing its future commercial development," says Anna Sjöblom-Hallén, project manager at MIVAC Development AB.

Click to read more about the Alzheimer's research findings.